|
US7138262B1
(en)
|
2000-08-18 |
2006-11-21 |
Shire Human Genetic Therapies, Inc. |
High mannose proteins and methods of making high mannose proteins
|
|
JP5303458B2
(ja)
|
2006-06-23 |
2013-10-02 |
アミークス セラピューティックス インコーポレイテッド |
β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
|
|
GB0622702D0
(en)
*
|
2006-11-15 |
2006-12-27 |
Univ Dundee |
Selective glycosidase inhibitors
|
|
EP2154969B1
(en)
|
2007-05-16 |
2015-11-18 |
The Brigham and Women's Hospital, Inc. |
Treatment of synucleinopathies
|
|
AU2009262670B2
(en)
*
|
2008-06-26 |
2013-06-20 |
Zevra Denmark A/S |
Use of Hsp70 as a regulator of enzymatic activity
|
|
WO2010056413A2
(en)
*
|
2008-11-14 |
2010-05-20 |
Parkinson's Institute |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION
|
|
GB0906159D0
(en)
*
|
2009-04-09 |
2009-05-20 |
Summit Corp Plc |
Drug combination for the treatment of proteostatic diseases
|
|
CA2758187C
(en)
*
|
2009-04-09 |
2017-03-07 |
Robert Boyd |
Methods for preventing and/or treating degenerative disorders of the central nervous system
|
|
US8940766B2
(en)
*
|
2009-04-09 |
2015-01-27 |
Amicus Therapeutics, Inc. |
Methods for preventing and/or treating lysosomal storage disorders
|
|
US9206457B2
(en)
*
|
2009-05-26 |
2015-12-08 |
Amicus Therapeutics, Inc. |
Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
|
|
US20110070643A1
(en)
*
|
2009-05-26 |
2011-03-24 |
Do Hung V |
Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
|
|
AU2010281403B2
(en)
*
|
2009-07-28 |
2016-03-10 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for treating Gaucher disease
|
|
WO2011049737A1
(en)
*
|
2009-10-19 |
2011-04-28 |
Amicus Therapeutics, Inc. |
Novel compositions for preventing and/or treating lysosomal storage disorders
|
|
SI2490532T1
(sl)
*
|
2009-10-19 |
2017-03-31 |
Amicus Therapeutics, Inc. |
Novi sestavki za preventivo in/ali zdravljenje degenerativnih motenj centralnega živčnega sistema
|
|
WO2011049787A1
(en)
*
|
2009-10-19 |
2011-04-28 |
Amicus Therapeutics, Inc. |
Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
|
|
CA2817773A1
(en)
|
2010-11-30 |
2012-06-07 |
Orphazyme Aps |
Methods for increasing intracellular activity of hsp70
|
|
DK2707101T3
(da)
|
2011-05-12 |
2019-05-13 |
Proteostasis Therapeutics Inc |
Proteostaseregulatorer
|
|
EP2533051A1
(en)
|
2011-06-06 |
2012-12-12 |
Centogene GmbH |
Method for the diagnosis of Gaucher's disease
|
|
WO2012177997A1
(en)
*
|
2011-06-22 |
2012-12-27 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
CA2861464C
(en)
|
2012-01-25 |
2018-03-06 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating tricyclic compounds
|
|
JP2016503405A
(ja)
*
|
2012-11-05 |
2016-02-04 |
ジェンザイム・コーポレーション |
タンパク質症を処置するための組成物および方法
|
|
WO2014089449A1
(en)
|
2012-12-07 |
2014-06-12 |
Rush University Nedical Center |
Composition and method for treating neuronal ceroid lipofuscinosis
|
|
WO2015095963A1
(en)
|
2013-12-23 |
2015-07-02 |
Alectos Therapeutics Inc. |
Glucocerebrosidase modulators and uses thereof
|
|
US9675627B2
(en)
|
2014-04-14 |
2017-06-13 |
Amicus Therapeutics, Inc. |
Dosing regimens for treating and/or preventing cerebral amyloidoses
|
|
AU2015317447B2
(en)
|
2014-09-15 |
2021-02-25 |
Zevra Denmark A/S |
Arimoclomol formulation
|
|
HRP20240644T1
(hr)
|
2014-11-06 |
2024-08-02 |
Bial-R&D Investments, S.A. |
Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
|
|
EP3292206B8
(en)
|
2015-05-07 |
2022-02-09 |
Takeda Pharmaceutical Company Limited |
Glucocerebrosidase gene therapy for parkinson's disease
|
|
CA3020305A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
US11192892B2
(en)
|
2016-04-06 |
2021-12-07 |
Bial—R&D Investments, S.A. |
Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
|
|
EP3440081A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
US10898476B2
(en)
|
2016-04-13 |
2021-01-26 |
Orphazyme A/S |
Heat shock proteins and cholesterol homeostasis
|
|
DK3782624T3
(da)
|
2016-04-29 |
2025-12-15 |
Zevra Denmark As |
Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
|
|
SG11201809693SA
(en)
|
2016-05-05 |
2018-11-29 |
Lysosomal Therapeutics Inc |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
EP3264092A1
(en)
*
|
2016-07-01 |
2018-01-03 |
Centogene AG |
Use of lyso-gb1 as druggable target
|
|
CN111278439A
(zh)
*
|
2017-10-26 |
2020-06-12 |
夏尔人类遗传性治疗公司 |
包含葡萄糖脑苷脂酶和异烟肼的调配物
|
|
CN108428452B
(zh)
|
2018-03-14 |
2019-12-13 |
百度在线网络技术（北京）有限公司 |
终端支架和远场语音交互系统
|
|
CN112585130A
(zh)
|
2018-06-27 |
2021-03-30 |
蛋白质平衡治疗股份有限公司 |
蛋白酶体活性增强化合物
|
|
BR112020026580A2
(pt)
|
2018-06-27 |
2021-03-23 |
Proteostasis Therapeutics, Inc. (Fem) |
Compostos, composição farmacêutica e métodos para tratar um paciente
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
CA3121785A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Washington University |
Methods of detecting, preventing, reversing, and treating neurological diseases
|
|
JP7642561B2
(ja)
*
|
2019-04-25 |
2025-03-10 |
武田薬品工業株式会社 |
イソファゴミン塩、その使用方法および製剤
|
|
CN111450306B
(zh)
*
|
2020-03-06 |
2021-11-19 |
大连理工大学 |
外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法
|
|
KR20230128462A
(ko)
|
2020-11-19 |
2023-09-05 |
제브라 덴마크 에이/에스 |
아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
|
|
EP4329881A4
(en)
*
|
2021-04-30 |
2025-06-11 |
Vanqua Bio, Inc. |
Small molecule modulators of glucocerebrosidase activity and uses thereof
|